Performance of BBIO BridgeBio Pharma | -2.7% in 12m
Compare BBIO with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare BridgeBio Pharma with its related Sector/Index XBI
Performance Duell BBIO vs XBI
| TimeFrame | BBIO | XBI |
|---|---|---|
| 1 Week | 2.63% | 2.28% |
| 1 Month | -3.09% | -1.93% |
| 3 Months | -8.84% | -0.58% |
| 6 Months | -1.51% | 15.17% |
| 12 Months | -2.68% | 45.22% |
| YTD | -37.3% | 10.22% |
| Rel. Perf. 1m | -0.28 | |
| Rel. Perf. 3m | -2.09 | |
| Rel. Perf. 6m | -1.50 | |
| Rel. Perf. 12m | -3.67 | |
| Spearman 1m | -0.31 | -0.549 |
| Spearman 3m | -0.15 | 0.010 |
Is BridgeBio Pharma a good stock to buy?
No, based on ValueRay Fundamental Analyses, BridgeBio Pharma (NASDAQ:BBIO) is currently (October 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -56.48 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBIO as of October 2024 is 22.41. This means that BBIO is currently overvalued and has a potential downside of -11.7% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBIO as of October 2024 is 22.41. This means that BBIO is currently overvalued and has a potential downside of -11.7% (Sold with Premium).
Is BBIO a buy, sell or hold?
- Strong Buy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: BBIO is performing better - Values below 0%: BBIO is underperforming
Compare BBIO with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 1.48% | -6.42% | -17.17% | -39.27% |
| US NASDAQ 100 | QQQ | 2.31% | -6.96% | -15.72% | -38.69% |
| US Dow Jones Industrial 30 | DIA | 1.03% | -5.83% | -15.79% | -31.97% |
| German DAX 40 | DBXD | 0.39% | -7.71% | -9.26% | -33.12% |
| UK FTSE 100 | ISFU | 1.75% | -2.14% | -12.42% | -26.86% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 14.48% | -21.89% | -12.35% | -12.72% |
| Hongkong Hang Seng | HSI | 7.27% | -14.55% | -23.76% | -12.34% |
| Japan Nikkei 225 | EXX7 | 2.73% | -7.41% | -2.70% | -25.94% |
| India NIFTY 50 | INDA | 2.77% | -1.15% | -12.71% | -31.58% |
| Brasil Bovespa | EWZ | 4.60% | 2.24% | 3.27% | -3.57% |
BBIO BridgeBio Pharma vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 1.97% | -7.13% | -15.54% | -39.63% |
| Consumer Discretionary | XLY | 2.18% | -6.28% | -15.60% | -28.85% |
| Consumer Staples | XLP | 0.87% | -1.51% | -15.84% | -27.34% |
| Energy | XLE | 4.05% | -7.65% | 2.67% | -3.67% |
| Financial | XLF | -0.79% | -7.48% | -20.07% | -46.52% |
| Health Care | XLV | 1.93% | -0.66% | -12.61% | -22.26% |
| Industrial | XLI | 0.64% | -8.72% | -15.51% | -42.06% |
| Materials | XLB | 0.63% | -6.53% | -10.16% | -30.10% |
| Real Estate | XLRE | 0.44% | -1.39% | -24.61% | -38.48% |
| Technology | XLK | 2.30% | -7.41% | -15.39% | -40.04% |
| Utilities | XLU | 1.21% | -5.64% | -30.12% | -43.26% |
| Aerospace & Defense | XAR | 1.42% | -8.25% | -22.72% | -40.30% |
| Biotech | XBI | 0.35% | -1.16% | -16.68% | -47.90% |
| Homebuilder | XHB | 1.20% | -5.97% | -22.14% | -73.46% |
| Retail | XRT | 0.58% | -5.37% | -11.12% | -31.96% |
Does BridgeBio Pharma outperform its market, is BBIO a Sector Leader?
No, over the last 12 months BridgeBio Pharma (BBIO) made -2.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 45.22%.
Over the last 3 months BBIO made -8.84%, while XBI made -0.58%.
No, over the last 12 months BridgeBio Pharma (BBIO) made -2.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 45.22%.
Over the last 3 months BBIO made -8.84%, while XBI made -0.58%.
| Period | BBIO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -3.09% | -1.93% | 3.33% |
| 3 Months | -8.84% | -0.58% | 3.57% |
| 12 Months | -2.68% | 45.22% | 36.59% |